Skip to main content
Fig. 1 | Harm Reduction Journal

Fig. 1

From: Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

Fig. 1

FAERS AE reports. FAERS AE reports for A concomitant fentanyl and DAA use B concomitant oxycodone/hydrocodone and DAA use C overdose AEs and deaths irrespective of concomitant opioid use. AEs, adverse events; DAA, direct-acting antiviral; EBR/GZR, elbasvir/grazoprevir; FAERS, US Food and Drug Administration Adverse Event Reporting System; G/P, glecaprevir/pibrentasvir; LDV/SOF, ledipasvir/sofosbuvir; SOF/VEL, sofosbuvir/velpatasvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir

Back to article page

Harm Reduction Journal

ISSN: 1477-7517